Arrowhead Pharmaceuticals Partners with Sarepta to Enhance Rare Disease Treatment Pipeline

Arrowhead Pharmaceuticals Partners with Sarepta Therapeutics to Expand Rare Disease Pipeline

Arrowhead Pharmaceuticals, a pioneer in RNA interference (RNAi) therapies, recently enters a transformative global licensing and collaboration agreement with Sarepta Therapeutics. This partnership aims to bolster Arrowhead’s capabilities in developing innovative treatments for rare genetic diseases affecting muscle, central nervous system (CNS), and lung functions. With this agreement, Sarepta secures exclusive global rights to several of Arrowhead’s clinical, preclinical, and discovery-stage programs, which include targeted therapies for conditions like facioscapulohumeral muscular dystrophy and myotonic dystrophy.

The collaboration aligns strategically with Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform, which is designed to deliver small interfering RNA (siRNA) for effective gene suppression. Key programs under this partnership include ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-DM1 for myotonic dystrophy type 1, and ARO-MMP7 for idiopathic pulmonary fibrosis, among others. The agreement also includes a discovery phase that allows Sarepta to select up to six new targets for Arrowhead to develop, enhancing the potential for advancing treatments for rare diseases.

This collaboration is anticipated to significantly extend Arrowhead's cash runway into 2028, providing the financial resources necessary for multiple drug launches. It also marks a strategic shift for Arrowhead as it transitions from a development-focused entity to one poised for commercial success. Doug Ingram, Sarepta’s president and CEO, joining Arrowhead's Board of Directors, further underscores the partnership's potential to bring additional clinical and regulatory expertise, ensuring a streamlined pathway toward commercialization of these promising therapeutics.

In addition to the immediate financial benefits, this agreement represents a long-term commitment to advancing rare disease therapies. Arrowhead is also preparing for the launch of its investigational product, plozasiran, for familial chylomicronemia syndrome, which is anticipated to receive FDA approval in 2025. This positioning underscores Arrowhead's commitment to addressing unmet medical needs in rare diseases, leveraging its advanced RNAi technology alongside Sarepta's established expertise in genetic medicine.